Showing results (321-330 of 357) with videos related to

Sort By:
Pageof 36
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1990
Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastomaP A Humphrey, A J Wong, B Vogelstein, et al.
Neurosurgery|March 1, 1986
Efficacy of vincristine and cyclophosphamide in the therapy of recurrent medulloblastomaH S Friedman, M S Mahaley, S C Schold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1989
Phase II treatment of medulloblastoma and pineoblastoma with melphalan: clinical therapy based on experimental models of human medulloblastomaH S Friedman, S C Schold, M S Mahaley, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
The effect of L-amino acid oxidase on activity of melphalan against an intracranial xenograftJ N Rich, G B Elion, D Wellner, et al.
Journal of Neuro-Oncology|March 17, 2000
Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude ratsG E Archer, J H Sampson, R E McLendon, et al.
The New England Journal of Medicine|June 17, 1993
Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumorsP K Duffner, M E Horowitz, J P Krischer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1987
Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasmsS C Schold, M S Mahaley, N A Vick, et al.
Cancer Research|March 15, 1990
Activity of intrathecal 4-hydroperoxycyclophosphamide in a nude rat model of human neoplastic meningitisH E Fuchs, G E Archer, O M Colvin, et al.
The American Journal of Pathology|August 6, 1999
Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridizationS H Bigner, M R Matthews, B K Rasheed, et al.
British Journal of Cancer|September 15, 2012
Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumoursA O von Bueren, M D Bacolod, C Hagel, et al.
Pageof 36